PlainPill

Fluoxetine

Also known as Prozac

The short answer. Most people who report on Fluoxetine say it did not help (only 26% of 73 positive). It is most often used for mood: 65% of 48 reports say that improved. It is well studied — 534 meta-analyses on PubMed. The most common complaint is sexual dysfunction.

What users report
26%helped73 reports · medium confidence
19 helped20 mixed33 didn't help

From 119 mentions in total — the rest didn't say how it went and aren't counted.

Clinical research
AStrong research base
534
meta-analyses
1,257
RCTs
15,365
papers
Prescription medication. These are self-reported experiences, not dosing or treatment advice. Prescription drugs have real side effects and interactions — start, stop or change them only with a doctor. Share of positive reports is not a measure of safety.

What Fluoxetine does, according to users

Of the people who reported each effect, the share who said it got better.

What the research says

Systematic reviews and meta-analyses from PubMed, with their published conclusions.

AStrong research base

3+ meta-analyses or systematic reviews and 10+ randomized controlled trials in humans. The grade measures how much human research exists — read the conclusions below for what it found. 534 meta-analyses on PubMed ↗ · 1,257 randomized trials ↗

Lancet · 2018 · Meta-analysis / systematic review
Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis

Conclusion: All antidepressants were more efficacious than placebo in adults with major depressive disorder. Smaller differences between active drugs were found when placebo-controlled trials were included in the analysis, whereas there was more variability in efficacy and acceptability in head-to-head trials. These results should serve evidence-based practice and inform patients, physicians, guideline developers, and policy makers on the relative merits of the different antidepressants.

PubMed 29477251 ↗
Lancet Psychiatry · 2024 · Meta-analysis / systematic review
Pharmacological treatments for psychotic depression: a systematic review and network meta-analysis

Conclusion: According to the available evidence, the combination of a selective serotonin reuptake inhibitor and a second-generation antipsychotic-and particularly of fluoxetine and olanzapine-could be the optimal treatment choice for psychotic depression. These findings should be taken into account in the development of clinical practice guidelines. However, these conclusions should be interpreted cautiously in view of the low number of included studies and the limitations of these studies.

PubMed 38360024 ↗
Lancet · 2019 · Meta-analysis / systematic review
Pharmacological treatments for generalised anxiety disorder: a systematic review and network meta-analysis

Conclusion: To our knowledge, this is the largest contemporary review of pharmacological agents for the treatment of generalised anxiety disorder by use of network analysis. There are several effective treatment choices for generalised anxiety disorder across classes of medication. The failure of initial pharmacological therapy might not be a reason to abandon a pharmacological treatment strategy.

PubMed 30712879 ↗
Mol Psychiatry · 2023 · Meta-analysis / systematic review
Antidepressants for the treatment of adults with major depressive disorder in the maintenance phase: a systematic review and network meta-analysis

Conclusion: Compared to placebo, venlafaxine was associated with a lower incidence of dizziness, while desvenlafaxine, sertraline, and vortioxetine were associated with a higher incidence of nausea/vomiting. In conclusion, desvenlafaxine, paroxetine, venlafaxine, and vortioxetine had reasonable efficacy, acceptability, and tolerability in the treatment of adults with stable MDD.

PubMed 36253442 ↗
Registered clinical trials

386 human trials on ClinicalTrials.gov test Fluoxetine — 245 completed, 33 recruiting now. See all on ClinicalTrials.gov ↗

What government agencies say

Official records from US, Canadian and EU regulators, each linked to its source.

FDA drug label

Boxed warning (the FDA's strongest label warning): “SUICIDAL THOUGHTS AND BEHAVIORS Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term studies. These studies did not show an increase in the risk of suicidal thoughts and behavior with antidepressant use in patients over age…”

Full label on DailyMed (NIH) ↗

Hidden in other products (FDA)

The FDA found Fluoxetine as an undeclared ingredient in 24 products sold as supplements, most recently on 2026-06-04. FDA tainted-products database ↗

FDA recalls

11 recalls of products named for Fluoxetine. Most recent:

  • 2025-06-11 · Class II: CGMP Deviations: Presence of N-Nitroso Fluoxetine exceeding interim acceptable intake limit. record ↗
  • 2018-02-21 · Class III: Failed impurities/ degradation specifications: Teva Pharmaceuticals USA, Inc. is voluntarily recalling all lots within expiry due to out of specification… record ↗
  • 2015-05-06 · Class II: Chemical Contamination: Product recalled due to an elevated level of a residual solvent impurity in the API that exceeds the Threshold of Toxicological… record ↗

Class I = could cause serious harm; Class II = temporary or reversible harm; Class III = unlikely to cause harm. Recalls are of specific products and lots, not of the ingredient itself. All recalls (openFDA) ↗

Reports to the FDA about the drug (FAERS)

131,827 adverse-event reports mention Fluoxetine. Most often reported:

  • Drug ineffective · 8,387
  • Nausea · 7,747
  • Fatigue · 7,712
  • Headache · 6,584
  • Depression · 6,131
  • Anxiety · 5,974

Reports often involve several drugs and serious illness; a report doesn't prove the drug caused the problem, and these counts can't tell you how often it happens. Source query (openFDA) ↗

Liver safety (LiverTox, NIH)

LiverTox rates Fluoxetine C — a probable rare cause of liver injury (3–12 published cases). LiverTox entry ↗

US government research funding (NIH)

NIH has funded 65 research projects with Fluoxetine in the title, $58,138,520 in total (1985–2026). NIH RePORTER ↗

Plain-language guides from the US government: MedlinePlus: Fluoxetine ↗

Dosage people report

We don't list doses for prescription medications. Dosing should only come from a doctor or pharmacist.

Reported side effects

How often each side effect came up across all reports.

sexual dysfunction ×6fatigue ×2headache ×2anorgasmia ×1pssd ×1ed ×1libido loss ×1zombification ×1

What users say

First-hand experiences, quoted verbatim. We show one positive and one negative where both exist.

Fluoxetine compared

Other options for mood

Sources

User data from public discussions; research from PubMed. Information only, not medical advice — talk to a doctor before starting, stopping or combining anything. Data updated October 5, 2026. How we rate